RU2661406C2 - Способы лечения заболеваний, ассоциированных с s. aureus - Google Patents

Способы лечения заболеваний, ассоциированных с s. aureus Download PDF

Info

Publication number
RU2661406C2
RU2661406C2 RU2015121617A RU2015121617A RU2661406C2 RU 2661406 C2 RU2661406 C2 RU 2661406C2 RU 2015121617 A RU2015121617 A RU 2015121617A RU 2015121617 A RU2015121617 A RU 2015121617A RU 2661406 C2 RU2661406 C2 RU 2661406C2
Authority
RU
Russia
Prior art keywords
seq
nos
amino acid
acid sequence
antibody
Prior art date
Application number
RU2015121617A
Other languages
English (en)
Russian (ru)
Other versions
RU2015121617A (ru
Inventor
Брет СЕЛЛМАН
Кристин ТКАЧИК
Мелисса ХЭМИЛТОН
Лэй ХУА
Original Assignee
МЕДИММЬЮН, ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by МЕДИММЬЮН, ЭлЭлСи filed Critical МЕДИММЬЮН, ЭлЭлСи
Publication of RU2015121617A publication Critical patent/RU2015121617A/ru
Application granted granted Critical
Publication of RU2661406C2 publication Critical patent/RU2661406C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
RU2015121617A 2012-11-06 2013-11-05 Способы лечения заболеваний, ассоциированных с s. aureus RU2661406C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261723128P 2012-11-06 2012-11-06
US61/723,128 2012-11-06
PCT/US2013/068385 WO2014074470A1 (en) 2012-11-06 2013-11-05 Methods of treating s. aureus-associated diseases

Publications (2)

Publication Number Publication Date
RU2015121617A RU2015121617A (ru) 2016-12-27
RU2661406C2 true RU2661406C2 (ru) 2018-07-16

Family

ID=50685101

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015121617A RU2661406C2 (ru) 2012-11-06 2013-11-05 Способы лечения заболеваний, ассоциированных с s. aureus

Country Status (13)

Country Link
US (3) US9845348B2 (enExample)
EP (1) EP2928490B1 (enExample)
JP (2) JP6506172B2 (enExample)
KR (3) KR20210083389A (enExample)
CN (2) CN112316135A (enExample)
AU (2) AU2013341421A1 (enExample)
BR (1) BR112015010126B1 (enExample)
CA (1) CA2890385C (enExample)
ES (1) ES2912267T3 (enExample)
MX (1) MX367082B (enExample)
RU (1) RU2661406C2 (enExample)
SG (2) SG10201703677VA (enExample)
WO (1) WO2014074470A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012267732A1 (en) 2011-06-10 2014-01-09 Medimmune Limited Anti-Pseudomonas Psl binding molecules and uses thereof
WO2013070615A1 (en) * 2011-11-07 2013-05-16 Medlmmune, Llc. Combination therapies using anti- pseudomonas psl and pcrv binding molecules
EP2917360B1 (en) * 2012-11-06 2020-01-08 Medlmmune, LLC Antibodies to s. aureus surface determinants
ES2912267T3 (es) * 2012-11-06 2022-05-25 Medimmune Llc Métodos de tratamiento de enfermedades asociadas a S. aureus
TWI719938B (zh) 2014-06-19 2021-03-01 美商麥迪紐有限責任公司 多重細菌感染之治療
TW202311284A (zh) 2017-01-03 2023-03-16 美商再生元醫藥公司 抗金黃色葡萄球菌溶血素a毒素之人類抗體
MX2021000889A (es) 2018-07-24 2021-04-28 Medimmune Llc Anticuerpo dirigido contra el factor de agregación a (clfa) de s. aureus.
WO2020076790A1 (en) 2018-10-09 2020-04-16 Medimmune, Llc Antibodies directed against staphylococcus aureus leukotoxins
MX2021004173A (es) 2018-10-09 2021-09-08 Medimmune Llc Combinaciones de anticuerpos dirigidos contra staphylococcus aureus.
JP7682795B2 (ja) 2019-03-13 2025-05-26 メディミューン,エルエルシー コロニー形成患者における黄色ブドウ球菌(Staphylococcus aureus)感染症の低減
CN112538112B (zh) * 2019-09-20 2023-10-27 迈威(上海)生物科技股份有限公司 抗α-溶血素的抗体及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120201829A1 (en) * 2009-08-10 2012-08-09 Michael Rudolf Human Monoclonal Antibody Against S. Aureus Derived Alpha-Toxin and Its Use in Treating or Preventing Abscess Formation
WO2012109285A2 (en) * 2011-02-08 2012-08-16 Medimmune, Llc Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use
WO2012109167A1 (en) * 2011-02-08 2012-08-16 Integrated Biotherapeutics, Inc. Immunogenic composition comprising alpha-hemolysin oligopeptides

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009539979A (ja) * 2006-06-12 2009-11-19 ナビ バイオファーマシューティカルズ ブドウ球菌感染症を治療および予防するための、α毒素の使用
KR20100072228A (ko) * 2007-08-31 2010-06-30 유니버시티 오브 시카고 스타필로코커스 폐 질환 및 상태에 대한 면역화와 관련된 방법 및 조성물
EP2453881A2 (en) * 2009-07-16 2012-05-23 Georgia Health Sciences University Research Institute, Inc. Porous-wall hollow glass microspheres as carriers for biomolecules
EP2917360B1 (en) 2012-11-06 2020-01-08 Medlmmune, LLC Antibodies to s. aureus surface determinants
ES2912267T3 (es) * 2012-11-06 2022-05-25 Medimmune Llc Métodos de tratamiento de enfermedades asociadas a S. aureus
TWI719938B (zh) 2014-06-19 2021-03-01 美商麥迪紐有限責任公司 多重細菌感染之治療
US20190077851A1 (en) 2015-10-30 2019-03-14 Bruno Francois Methods of using anti-alpha toxin antibody

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120201829A1 (en) * 2009-08-10 2012-08-09 Michael Rudolf Human Monoclonal Antibody Against S. Aureus Derived Alpha-Toxin and Its Use in Treating or Preventing Abscess Formation
WO2012109285A2 (en) * 2011-02-08 2012-08-16 Medimmune, Llc Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use
WO2012109167A1 (en) * 2011-02-08 2012-08-16 Integrated Biotherapeutics, Inc. Immunogenic composition comprising alpha-hemolysin oligopeptides

Also Published As

Publication number Publication date
EP2928490B1 (en) 2022-03-30
AU2018236849A1 (en) 2018-10-18
KR20210083389A (ko) 2021-07-06
SG11201503231YA (en) 2015-05-28
US10457724B2 (en) 2019-10-29
KR102272744B1 (ko) 2021-07-06
JP6506172B2 (ja) 2019-04-24
KR20200102533A (ko) 2020-08-31
CN112316135A (zh) 2021-02-05
CN104780934A (zh) 2015-07-15
AU2013341421A1 (en) 2015-06-04
JP6926138B2 (ja) 2021-08-25
CA2890385C (en) 2022-07-12
SG10201703677VA (en) 2017-06-29
JP2019142888A (ja) 2019-08-29
ES2912267T3 (es) 2022-05-25
US10759849B2 (en) 2020-09-01
RU2015121617A (ru) 2016-12-27
CA2890385A1 (en) 2014-05-15
US9845348B2 (en) 2017-12-19
US20200109191A1 (en) 2020-04-09
MX2015005481A (es) 2016-01-14
HK1215173A1 (zh) 2016-08-19
MX367082B (es) 2019-08-05
WO2014074470A1 (en) 2014-05-15
AU2018236849B2 (en) 2020-05-21
US20160257733A1 (en) 2016-09-08
US20190002540A1 (en) 2019-01-03
EP2928490A4 (en) 2016-11-02
JP2015536951A (ja) 2015-12-24
BR112015010126A2 (enExample) 2017-08-22
BR112015010126B1 (pt) 2022-11-01
KR20150092738A (ko) 2015-08-13
EP2928490A1 (en) 2015-10-14

Similar Documents

Publication Publication Date Title
US10759849B2 (en) Methods of treating S. aureus-associated diseases
KR102288394B1 (ko) 스타필로코커스 아우레우스 표면 결정인자에 대한 항체
KR101993839B1 (ko) 스타필로코커스 아우레우스 알파 독소에 특이적으로 결합하는 항체 및 이의 사용 방법
US20150044168A1 (en) Treatment of Multiple Sclerosis With Anti-CD19 Antibody
US12570744B2 (en) Bispecific PD-1 and TIGIT binding proteins and uses thereof
US20240109961A1 (en) Treatment of chronic prurigo
HK1215173B (en) Methods of treating s. aureus-associated diseases
TW202506180A (zh) 用於癌症治療之pd-1/tigit結合蛋白
TW202511292A (zh) 用於治療NSCLC及cHL之PD-1/TIM-3結合蛋白
WO2025250726A1 (en) Anti-kit antibody dosing and methods
CN119654169A (zh) 抗体-药物缀合物和双特异性检查点抑制剂的组合
CN117120089A (zh) 慢性痒疹的治疗